AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Titratable Dosing in Moderate to Severe Asthmatics
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: budesonide/formoterol
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 570
- Registration Number
- NCT00651768
Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT00652002
Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT00651651
Gemini Symbicort pMDI
Phase 3
Completed
- Conditions
- Mild or Moderate Asthma
- Interventions
- Drug: budesonide/formoterol (Symbicort)
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 615
- Registration Number
- NCT00646516
Long-term Safety in Atrial Fibrillation Patients
Phase 2
Completed
- Conditions
- Persistent or Permanent Nonvalvular Atrial Fibrillation
- Interventions
- Drug: VKA INR 2-3
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2012-03-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 523
- Registration Number
- NCT00645853
Symbicort Onset of Action 1
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: fluticasone/salmeterol (Advair Diskus)Drug: budesonide/formoterol (Symbicort)
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2009-04-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT00646620
Long-Term Safety of Symbicort in Asthmatic Children - SAPLING
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: budesonide/formoterol (Symbicort)
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2009-03-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 175
- Registration Number
- NCT00646529
Atlantis Symbicort
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: budesonide/formoterol (Symbicort)Drug: fluticasone/salmeterol (Advair)
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2009-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1200
- Registration Number
- NCT00646594
Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUT
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: budesonide/formoterol (Symbicort)
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 540
- Registration Number
- NCT00646321
Symbicort Onset of Action 2
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT00646009
© Copyright 2025. All Rights Reserved by MedPath